A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
Latest Information Update: 13 May 2024
At a glance
- Drugs Barzolvolimab (Primary)
- Indications Prurigo nodularis
- Focus Adverse reactions
- Sponsors Celldex Therapeutics Inc
- 26 Feb 2024 According to a Celldex Therapeutics media release, data from the Phase 1b randomized, double-blind, placebo-controlled study in patients with prurigo nodularis were reported in an oral presentation at the 12th World Congress on Itch (WCI) in November 2023.
- 02 Nov 2023 According to a Celldex Therapeutics media release, the data from the Phase 1b randomized, double-blind, placebo-controlled study in patients with prurigo nodularis have been accepted for oral presentation at the 12th World Congress on Itch (WCI), being held in Miami, and will be presented by Martin Metz.
- 26 Sep 2023 According to a Celldex Therapeutics media release, data from this phase 1b study will be presented at the12th World Congress on Itch (WCI).